{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:42Z","timestamp":1776408702314,"version":"3.51.2"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06872-x","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:35:21Z","timestamp":1772429721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Natural killer cells, macrophages and dendritic cells as innate immune therapies for blood cancers"],"prefix":"10.1007","volume":"105","author":[{"given":"Ghaleb","family":"Oriquat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-5783","authenticated-orcid":false,"given":"Waleed K.","family":"Abdulsahib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajida Hussein","family":"Ismael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Roopashree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeepta Sekhar","family":"Patro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayshree","family":"Nellore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunjan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish Singh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saodat","family":"Musayeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"8","key":"6872_CR1","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3390\/cancers15082323","volume":"15","author":"Y Yu","year":"2023","unstructured":"Yu Y (2023) The function of NK cells in tumor metastasis and NK Cell-Based immunotherapy. Cancers (Basel) 15(8):2323","journal-title":"Cancers (Basel)"},{"key":"6872_CR2","doi-asserted-by":"crossref","first-page":"621254","DOI":"10.3389\/fimmu.2020.621254","volume":"11","author":"EE Peterson","year":"2020","unstructured":"Peterson EE, Barry KC (2020) The natural Killer-Dendritic cell immune axis in Anti-Cancer immunity and immunotherapy. Front Immunol 11:621254","journal-title":"Front Immunol"},{"issue":"8","key":"6872_CR3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807\u2013821","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"6872_CR4","first-page":"e714","volume":"5","author":"R Wang","year":"2020","unstructured":"Wang R, Lan C, Benlagha K, Camara NOS, Miller H, Kubo M et al (2020) The interaction of innate immune and adaptive immune system. MedComm 2024 5(10):e714","journal-title":"MedComm 2024"},{"issue":"Pt 2","key":"6872_CR5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.semcancer.2022.08.004","volume":"86","author":"S Yenyuwadee","year":"2022","unstructured":"Yenyuwadee S, Aliazis K, Wang Q, Christofides A, Shah R, Patsoukis N et al (2022) Immune cellular components and signaling pathways in the tumor microenvironment. Semin Cancer Biol 86(Pt 2):187\u2013201","journal-title":"Semin Cancer Biol"},{"key":"6872_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-3-030-49270-0_4","volume":"1273","author":"C Guillerey","year":"2020","unstructured":"Guillerey C (2020) NK cells in the tumor microenvironment. Adv Exp Med Biol 1273:69\u201390","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"6872_CR7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/CCO.0000000000000968","volume":"35","author":"M Sayegh","year":"2023","unstructured":"Sayegh M, Ma S, Yu J (2023) Application of natural killer immunotherapy in blood cancers and solid tumors. Curr Opin Oncol 35(5):446\u2013452","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"6872_CR8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS (2021) Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol 18(2):85\u2013100","journal-title":"Nat Rev Clin Oncol"},{"issue":"12Supplement","key":"6872_CR9","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1538-7445.AM2022-6169","volume":"82","author":"ZX Malchiodi","year":"2022","unstructured":"Malchiodi ZX, Fitzgerald A, Galvano E, Weiner LM (2022) Identification of molecules mediating natural killer cell-pancreatic stellate cell interactions. Cancer Res 82(12Supplement):6169","journal-title":"Cancer Res"},{"key":"6872_CR10","doi-asserted-by":"crossref","first-page":"683381","DOI":"10.3389\/fimmu.2021.683381","volume":"12","author":"NM Kaweme","year":"2021","unstructured":"Kaweme NM, Zhou F (2021) Optimizing NK Cell-Based immunotherapy in myeloid leukemia: abrogating an immunosuppressive microenvironment. Front Immunol 12:683381","journal-title":"Front Immunol"},{"issue":"6","key":"6872_CR11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R et al (2020) Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med 382(6):545\u2013553","journal-title":"N Engl J Med"},{"issue":"13","key":"6872_CR12","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.3390\/cancers13133225","volume":"13","author":"I Mattiola","year":"2021","unstructured":"Mattiola I (2021) Immune circuits to shape natural killer cells in cancer. Cancers (Basel) 13(13):3225","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6872_CR13","first-page":"400","volume":"10","author":"LHR da Silva","year":"2022","unstructured":"da Silva LHR, Catharino LCC, da Silva VJ, Evangelista GCM, Barbuto JAM (2022) The war is on: the immune system against Glioblastoma-How can NK cells drive this battle? Biomed 10(2):400","journal-title":"Biomed"},{"key":"6872_CR14","doi-asserted-by":"crossref","first-page":"871106","DOI":"10.3389\/fimmu.2022.871106","volume":"13","author":"H Ham","year":"2022","unstructured":"Ham H, Medlyn M, Billadeau DD (2022) Locked and loaded: mechanisms regulating natural killer cell lytic granule biogenesis and release. Front Immunol 13:871106","journal-title":"Front Immunol"},{"key":"6872_CR15","doi-asserted-by":"crossref","first-page":"643310","DOI":"10.3389\/fimmu.2021.643310","volume":"12","author":"AG Bozward","year":"2021","unstructured":"Bozward AG, Warricker F, Oo YH, Khakoo SI (2021) Natural killer cells and regulatory T cells cross talk in hepatocellular carcinoma: exploring therapeutic options for the next decade. Front Immunol 12:643310","journal-title":"Front Immunol"},{"issue":"7","key":"6872_CR16","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers12071760","volume":"12","author":"AM Cornel","year":"2020","unstructured":"Cornel AM, Mimpen IL, Nierkens S (2020) MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel) 12(7):1760","journal-title":"Cancers (Basel)"},{"key":"6872_CR17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","volume":"8","author":"S Paul","year":"2017","unstructured":"Paul S, Lal G (2017) The molecular mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol 8:1124","journal-title":"Front Immunol"},{"issue":"1","key":"6872_CR18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y et al (2021) Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 6(1):263","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"6872_CR19","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.4049\/jimmunol.1003035","volume":"186","author":"JC Sun","year":"2011","unstructured":"Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL (2011) NK cells and immune memory. J Immunol 186(4):1891\u20131897","journal-title":"J Immunol"},{"key":"6872_CR20","first-page":"400","volume":"3","author":"G Terrazzano","year":"2012","unstructured":"Terrazzano G, Carbone E (2012) NK cells blur the frontier between innate and acquired immunity. Front Immunol 3:400","journal-title":"Front Immunol"},{"issue":"10","key":"6872_CR21","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/jcm8101557","volume":"8","author":"AP Gonzalez-Rodriguez","year":"2019","unstructured":"Gonzalez-Rodriguez AP, Villa-\u00c1lvarez M, Sordo-Bahamonde C, Lorenzo-Herrero S, Gonzalez S (2019) NK cells in the treatment of hematological malignancies. J Clin Med 8(10):1557","journal-title":"J Clin Med"},{"issue":"2","key":"6872_CR22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/vaccines9020138","volume":"9","author":"S Rameshbabu","year":"2021","unstructured":"Rameshbabu S, Labadie BW, Argulian A, Patnaik A (2021) Targeting innate immunity in cancer therapy. Vaccines (Basel) 9(2):138","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"6872_CR23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/atm.2019.01.42","volume":"7","author":"C Lo Nigro","year":"2019","unstructured":"Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC (2019) NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives. Ann Transl Med 7(5):105","journal-title":"Ann Transl Med"},{"issue":"3","key":"6872_CR24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00109-021-02120-z","volume":"100","author":"M Vogler","year":"2022","unstructured":"Vogler M, Shanmugalingam S, S\u00e4rchen V, Reindl LM, Gr\u00e8ze V, Buchinger L et al (2022) Unleashing the power of NK cells in anticancer immunotherapy. J Mol Med (Berl) 100(3):337\u2013349","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"6872_CR25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","volume":"20","author":"JW Leong","year":"2014","unstructured":"Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA et al (2014) Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transpl 20(4):463\u2013473","journal-title":"Biol Blood Marrow Transpl"},{"key":"6872_CR26","doi-asserted-by":"crossref","first-page":"859177","DOI":"10.3389\/fimmu.2022.859177","volume":"13","author":"M Tarannum","year":"2022","unstructured":"Tarannum M, Romee R, Shapiro RM (2022) Innovative strategies to improve the clinical application of NK Cell-Based immunotherapy. Front Immunol 13:859177","journal-title":"Front Immunol"},{"issue":"1","key":"6872_CR27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10238-025-01559-5","volume":"25","author":"M Rady","year":"2025","unstructured":"Rady M, Mostafa M, Dida G, Sabet F, Abou-Aisha K, Watzl C (2025) Adoptive NK cell therapy in AML: progress and challenges. Clin Exp Med 25(1):41","journal-title":"Clin Exp Med"},{"issue":"1","key":"6872_CR28","doi-asserted-by":"crossref","first-page":"103065","DOI":"10.1016\/j.transci.2021.103065","volume":"60","author":"RJ Golden","year":"2021","unstructured":"Golden RJ, Fesnak AD (2021) Clinical development of natural killer cells expressing chimeric antigen receptors. Transfus Apher Sci 60(1):103065","journal-title":"Transfus Apher Sci"},{"key":"6872_CR29","doi-asserted-by":"crossref","first-page":"584099","DOI":"10.3389\/fimmu.2020.584099","volume":"11","author":"X Zhao","year":"2020","unstructured":"Zhao X, Cai L, Hu Y, Wang H (2020) Cord-Blood natural killer Cell-Based immunotherapy for cancer. Front Immunol 11:584099","journal-title":"Front Immunol"},{"issue":"1","key":"6872_CR30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","volume":"14","author":"LV J\u00f8rgensen","year":"2025","unstructured":"J\u00f8rgensen LV, Christensen EB, Barnkob MB, Barington T (2025) The clinical landscape of CAR NK cells. Exp Hematol Oncol 14(1):46","journal-title":"Exp Hematol Oncol"},{"key":"6872_CR31","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2020.00888","volume":"11","author":"M Cerrano","year":"2020","unstructured":"Cerrano M, Ruella M, Perales MA, Vitale C, Faraci DG, Giaccone L et al (2020) The advent of CAR T-Cell therapy for lymphoproliferative neoplasms: integrating research into clinical practice. Front Immunol 11:888","journal-title":"Front Immunol"},{"issue":"11","key":"6872_CR32","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jtct.2021.08.016","volume":"27","author":"HE Heslop","year":"2021","unstructured":"Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE et al (2021) Blood and marrow transplant clinical trials network state of the science symposium 2021: looking forward as the network celebrates its 20th Year. Transplant Cell Ther 27(11):885\u2013907","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"6872_CR33","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/cells10123390","volume":"10","author":"A Bashiri Dezfouli","year":"2021","unstructured":"Bashiri Dezfouli A, Yazdi M, Pockley AG, Khosravi M, Kobold S, Wagner E et al (2021) NK cells armed with chimeric antigen receptors (CAR): roadblocks to successful development. Cells 10(12):3390","journal-title":"Cells"},{"issue":"10","key":"6872_CR34","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 21(10):1089\u20131108","journal-title":"Cell Mol Immunol"},{"key":"6872_CR35","doi-asserted-by":"crossref","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2024","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L (2024) CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol 15:1519671","journal-title":"Front Immunol"},{"issue":"1","key":"6872_CR36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12672-024-01195-7","volume":"15","author":"DC Joshi","year":"2024","unstructured":"Joshi DC, Sharma A, Prasad S, Singh K, Kumar M, Sherawat K et al (2024) Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy. Discov Oncol 15(1):342","journal-title":"Discov Oncol"},{"issue":"7","key":"6872_CR37","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3390\/cancers12071748","volume":"12","author":"A Kotsafti","year":"2020","unstructured":"Kotsafti A, Scarpa M, Castagliuolo I, Scarpa M (2020) Reactive oxygen species and antitumor immunity-from surveillance to evasion. Cancers (Basel) 12(7):1748","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6872_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","volume":"14","author":"R Huang","year":"2025","unstructured":"Huang R, Wang X, Yan H, Tan X, Ma Y, Wang M et al (2025) Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial. Exp Hematol Oncol 14(1):1","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"6872_CR39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J (2024) Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov 10(1):318","journal-title":"Cell Death Discov"},{"issue":"7","key":"6872_CR40","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/cancers13071568","volume":"13","author":"M Gurney","year":"2021","unstructured":"Gurney M, O\u2019Dwyer M (2021) Realizing innate potential: CAR-NK cell therapies for acute myeloid leukemia. Cancers (Basel) 13(7):1568","journal-title":"Cancers (Basel)"},{"issue":"1","key":"6872_CR41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","volume":"21","author":"L Tong","year":"2022","unstructured":"Tong L, Jim\u00e9nez-Cortegana C, Tay AHM, Wickstr\u00f6m S, Galluzzi L, Lundqvist A (2022) NK cells and solid tumors: therapeutic potential and persisting Obstacles. Mol Cancer 21(1):206","journal-title":"Mol Cancer"},{"key":"6872_CR42","doi-asserted-by":"crossref","first-page":"668731","DOI":"10.3389\/fonc.2021.668731","volume":"11","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Gaggar S, G\u00f6genur I (2021) Cancer-Associated fibroblasts and Tumor-Associated macrophages in cancer and cancer immunotherapy. Front Oncol 11:668731","journal-title":"Front Oncol"},{"issue":"1","key":"6872_CR43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-024-05033-w","volume":"22","author":"L Miao","year":"2024","unstructured":"Miao L, Lu C, Zhang B, Li H, Zhao X, Chen H et al (2024) Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy. J Transl Med 22(1):229","journal-title":"J Transl Med"},{"issue":"1","key":"6872_CR44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y et al (2024) Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer 23(1):261","journal-title":"Mol Cancer"},{"key":"6872_CR45","doi-asserted-by":"crossref","first-page":"1621885","DOI":"10.3389\/fimmu.2025.1621885","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhao Y, Dong Y, Jiang X (2025) NK cell-based immunotherapy strategies for myeloid leukemia. Front Immunol 16:1621885","journal-title":"Front Immunol"},{"issue":"1","key":"6872_CR46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","volume":"7","author":"GH Ran","year":"2022","unstructured":"Ran GH, Lin YQ, Tian L, Zhang T, Yan DM, Yu JH et al (2022) Natural killer cell homing and trafficking in tissues and tumors: from biology to application. Signal Transduct Target Ther 7(1):205","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"6872_CR47","first-page":"010371","volume":"13","author":"S Cho","year":"2025","unstructured":"Cho S, Choi SH, Maeng E, Park H, Ryu KS, Park KS (2025) Boosting tumor homing of endogenous natural killer cells via therapeutic secretomes of chemically primed natural killer cells. J Immunother Cancer 13(3):010371","journal-title":"J Immunother Cancer"},{"key":"6872_CR48","doi-asserted-by":"crossref","first-page":"1550652","DOI":"10.3389\/fimmu.2025.1550652","volume":"16","author":"JH Guo","year":"2025","unstructured":"Guo JH, Afzal A, Ahmad S, Saeed G, Rehman A, Saddozai UAK et al (2025) Novel strategies to overcome tumor immunotherapy resistance using CAR NK cells. Front Immunol 16:1550652","journal-title":"Front Immunol"},{"key":"6872_CR49","doi-asserted-by":"crossref","first-page":"1308681","DOI":"10.3389\/fonc.2023.1308681","volume":"13","author":"X Huang","year":"2023","unstructured":"Huang X, Ren Q, Yang L, Cui D, Ma C, Zheng Y et al (2023) Immunogenic chemotherapy: great potential for improving response rates. Front Oncol 13:1308681","journal-title":"Front Oncol"},{"issue":"1","key":"6872_CR50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13046-025-03375-x","volume":"44","author":"D Masmoudi","year":"2025","unstructured":"Masmoudi D, Villalba M, Alix-Panabi\u00e8res C (2025) Natural killer cells: the immune frontline against Circulating tumor cells. J Exp Clin Cancer Res 44(1):118","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"6872_CR51","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","volume":"21","author":"T Bald","year":"2020","unstructured":"Bald T, Krummel MF, Smyth MJ, Barry KC (2020) The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies. Nat Immunol 21(8):835\u2013847","journal-title":"Nat Immunol"},{"issue":"1","key":"6872_CR52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW (2014) Tumor-associated macrophages: from mechanisms to therapy. Immunity 41(1):49\u201361","journal-title":"Immunity"},{"issue":"5","key":"6872_CR53","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00432-024-05777-4","volume":"150","author":"R Huang","year":"2024","unstructured":"Huang R, Kang T, Chen S (2024) The role of tumor-associated macrophages in tumor immune evasion. J Cancer Res Clin Oncol 150(5):238","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"6872_CR54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.coi.2010.01.009","volume":"22","author":"A Mantovani","year":"2010","unstructured":"Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22(2):231\u2013237","journal-title":"Curr Opin Immunol"},{"key":"6872_CR55","first-page":"948098","volume":"2012","author":"NB Hao","year":"2012","unstructured":"Hao NB, L\u00fc MH, Fan YH, Cao YL, Zhang ZR, Yang SM (2012) Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol 2012:948098","journal-title":"Clin Dev Immunol"},{"issue":"11","key":"6872_CR56","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","volume":"10","author":"Q Yang","year":"2020","unstructured":"Yang Q, Guo N, Zhou Y, Chen J, Wei Q, Han M (2020) The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy. Acta Pharm Sin B 10(11):2156\u20132170","journal-title":"Acta Pharm Sin B"},{"key":"6872_CR57","doi-asserted-by":"crossref","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","volume":"14","author":"U Basak","year":"2023","unstructured":"Basak U, Sarkar T, Mukherjee S, Chakraborty S, Dutta A, Dutta S et al (2023) Tumor-associated macrophages: an effective player of the tumor microenvironment. Front Immunol 14:1295257","journal-title":"Front Immunol"},{"key":"6872_CR58","doi-asserted-by":"crossref","first-page":"1532833","DOI":"10.3389\/fimmu.2024.1532833","volume":"15","author":"D Chettri","year":"2024","unstructured":"Chettri D, Satapathy BP, Yadav R, Uttam V, Jain A, Prakash H (2024) CAR-macrophages: tailoring cancer immunotherapy. Front Immunol 15:1532833","journal-title":"Front Immunol"},{"issue":"1","key":"6872_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-023-00549-7","volume":"12","author":"Y Qian","year":"2024","unstructured":"Qian Y, Yin Y, Zheng X, Liu Z, Wang X (2024) Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities. Biomark Res 12(1):1","journal-title":"Biomark Res"},{"issue":"21","key":"6872_CR60","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1158\/0008-5472.CAN-20-1723","volume":"81","author":"DC Hinshaw","year":"2021","unstructured":"Hinshaw DC, Hanna A, Lama-Sherpa T, Metge B, Kammerud SC, Benavides GA et al (2021) Hedgehog signaling regulates metabolism and polarization of mammary Tumor-Associated macrophages. Cancer Res 81(21):5425\u20135437","journal-title":"Cancer Res"},{"key":"6872_CR61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cancers16193410","volume":"16","author":"A Ghebremedhin","year":"2024","unstructured":"Ghebremedhin A, Athavale D, Zhang Y, Yao X, Balch C, Song S (2024) Tumor-Associated macrophages as major immunosuppressive cells in the tumor microenvironment. Cancers (Basel) 16:19","journal-title":"Cancers (Basel)"},{"issue":"3","key":"6872_CR62","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1189\/jlb.0504272","volume":"76","author":"RD Stout","year":"2004","unstructured":"Stout RD, Suttles J (2004) Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 76(3):509\u2013513","journal-title":"J Leukoc Biol"},{"key":"6872_CR63","doi-asserted-by":"crossref","first-page":"642285","DOI":"10.3389\/fimmu.2021.642285","volume":"12","author":"TD Ricketts","year":"2021","unstructured":"Ricketts TD, Prieto-Dominguez N, Gowda PS, Ubil E (2021) Mechanisms of macrophage plasticity in the tumor environment: manipulating activation state to improve outcomes. Front Immunol 12:642285","journal-title":"Front Immunol"},{"issue":"5","key":"6872_CR64","first-page":"010437","volume":"13","author":"KS Park","year":"2025","unstructured":"Park KS, Gottlieb AP, Janes ME, Prakash S, Kapate N, Suja VC et al (2025) Adoptively transferred macrophages for cancer immunotherapy. J Immunother Cancer 13(5):010437","journal-title":"J Immunother Cancer"},{"issue":"9","key":"6872_CR65","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3390\/cells10092364","volume":"10","author":"M Reis-Sobreiro","year":"2021","unstructured":"Reis-Sobreiro M, Teixeira da Mota A, Jardim C, Serre K (2021) Bringing macrophages to the frontline against cancer: current immunotherapies targeting macrophages. Cells 10(9):2364","journal-title":"Cells"},{"issue":"9","key":"6872_CR66","doi-asserted-by":"crossref","first-page":"e19296","DOI":"10.1016\/j.heliyon.2023.e19296","volume":"9","author":"S Tan","year":"2023","unstructured":"Tan S, Tang H, Wang Y, Xie P, Li H, Zhang Z et al (2023) Tumor cell-derived exosomes regulate macrophage polarization: emerging directions in the study of tumor genesis and development. Heliyon 9(9):e19296","journal-title":"Heliyon"},{"issue":"1","key":"6872_CR67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","volume":"8","author":"S Wang","year":"2024","unstructured":"Wang S, Wang J, Chen Z, Luo J, Guo W, Sun L et al (2024) Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance. NPJ Precis Oncol 8(1):31","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"6872_CR68","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-025-02357-z","volume":"24","author":"H Sabit","year":"2025","unstructured":"Sabit H, Pawlik TM, Radwan F, Abdel-Hakeem M, Abdel-Ghany S, Wadan AS et al (2025) Precision nanomedicine: navigating the tumor microenvironment for enhanced cancer immunotherapy and targeted drug delivery. Mol Cancer 24(1):160","journal-title":"Mol Cancer"},{"key":"6872_CR69","doi-asserted-by":"crossref","first-page":"888713","DOI":"10.3389\/fimmu.2022.888713","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao J, Liang Y, Wang L (2022) Shaping polarization of Tumor-Associated macrophages in cancer immunotherapy. Front Immunol 13:888713","journal-title":"Front Immunol"},{"issue":"1","key":"6872_CR70","doi-asserted-by":"crossref","first-page":"49","DOI":"10.32604\/or.2023.042383","volume":"32","author":"Q Chen","year":"2023","unstructured":"Chen Q, Guo X, Ma W (2023) Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy. Oncol Res 32(1):49\u201360","journal-title":"Oncol Res"},{"issue":"4","key":"6872_CR71","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41419-024-06616-7","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Wang Y, Jia J, Fang Y, Yang Y, Yuan W et al (2024) Advances in engineered macrophages: A new frontier in cancer immunotherapy. Cell Death Dis 15(4):238","journal-title":"Cell Death Dis"},{"key":"6872_CR72","doi-asserted-by":"crossref","first-page":"1259034","DOI":"10.3389\/fonc.2023.1259034","volume":"13","author":"M Aizaz","year":"2023","unstructured":"Aizaz M, Khan A, Khan F, Khan M, Musad Saleh EA, Nisar M et al (2023) The cross-talk between macrophages and tumor cells as a target for cancer treatment. Front Oncol 13:1259034","journal-title":"Front Oncol"},{"key":"6872_CR73","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","volume":"63","author":"Y Liu","year":"2024","unstructured":"Liu Y, Weng L, Wang Y, Zhang J, Wu Q, Zhao P et al (2024) Deciphering the role of CD47 in cancer immunotherapy. J Adv Res 63:129\u2013158","journal-title":"J Adv Res"},{"key":"6872_CR74","doi-asserted-by":"crossref","first-page":"1378647","DOI":"10.3389\/fonc.2024.1378647","volume":"14","author":"C Jiang","year":"2024","unstructured":"Jiang C, Sun H, Jiang Z, Tian W, Cang S, Yu J (2024) Targeting the CD47\/SIRP\u03b1 pathway in malignancies: recent progress, difficulties and future perspectives. Front Oncol 14:1378647","journal-title":"Front Oncol"},{"issue":"5","key":"6872_CR75","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","volume":"52","author":"MEW Logtenberg","year":"2020","unstructured":"Logtenberg MEW, Scheeren FA, Schumacher TN (2020) The CD47-SIRP\u03b1 immune checkpoint. Immunity 52(5):742\u2013752","journal-title":"Immunity"},{"key":"6872_CR76","doi-asserted-by":"crossref","first-page":"103873","DOI":"10.1016\/j.ebiom.2022.103873","volume":"76","author":"S Wang","year":"2022","unstructured":"Wang S, Yang Y, Ma P, Zha Y, Zhang J, Lei A et al (2022) CAR-macrophage: an extensive immune enhancer to fight cancer. EBioMedicine 76:103873","journal-title":"EBioMedicine"},{"issue":"1","key":"6872_CR77","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-025-02124-y","volume":"10","author":"F Guan","year":"2025","unstructured":"Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y et al (2025) Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduct Target Ther 10(1):93","journal-title":"Signal Transduct Target Ther"},{"key":"6872_CR78","doi-asserted-by":"crossref","first-page":"1615760","DOI":"10.3389\/fimmu.2025.1615760","volume":"16","author":"A Morva","year":"2025","unstructured":"Morva A, Arroyo AB, Andreeva L, Tapia-Abell\u00e1n A, Luengo-Gil G (2025) Unleashing the power of CAR-M therapy in solid tumors: a comprehensive review. Front Immunol 16:1615760","journal-title":"Front Immunol"},{"key":"6872_CR79","doi-asserted-by":"crossref","first-page":"123300","DOI":"10.1016\/j.lfs.2024.123300","volume":"361","author":"Y Shi","year":"2025","unstructured":"Shi Y, Li X, Dong Y, Yuan H, Wang Y, Yang R (2025) Exploring the potential of CAR-macrophage therapy. Life Sci 361:123300","journal-title":"Life Sci"},{"issue":"4","key":"6872_CR80","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR et al (2025) CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med 31(4):1171\u20131182","journal-title":"Nat Med"},{"issue":"1","key":"6872_CR81","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40364-025-00783-1","volume":"13","author":"S Saeidpour Masouleh","year":"2025","unstructured":"Saeidpour Masouleh S, Nasiri K, Ostovar Ravari A, Saligheh Rad M, Kiani K, Sharifi Sultani A et al (2025) Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma. Biomark Res 13(1):69","journal-title":"Biomark Res"},{"key":"6872_CR82","doi-asserted-by":"crossref","first-page":"101481","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano AE, Anandasabapathy N (2021) The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol 52:101481","journal-title":"Semin Immunol"},{"key":"6872_CR83","doi-asserted-by":"crossref","first-page":"595841","DOI":"10.3389\/fimmu.2020.595841","volume":"11","author":"SB Boscardin","year":"2020","unstructured":"Boscardin SB, Dudziak D, M\u00fcnz C, Rosa DS (2020) Editorial: Harnessing the participation of dendritic cells in immunity and tolerance. Front Immunol 11:595841","journal-title":"Front Immunol"},{"issue":"5","key":"6872_CR84","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A, Laffranchi M, Sozio F, Bosisio D et al (2023) Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol 20(5):432\u2013447","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"6872_CR85","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/JLB.3MIR0320-475R","volume":"108","author":"RB Chang","year":"2020","unstructured":"Chang RB, Beatty GL (2020) The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. J Leukoc Biol 108(1):363\u2013376","journal-title":"J Leukoc Biol"},{"issue":"4","key":"6872_CR86","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265\u2013277","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"6872_CR87","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon.12.125","volume":"8","author":"JA Cintolo","year":"2012","unstructured":"Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ (2012) Dendritic cell-based vaccines: barriers and opportunities. Future Oncol 8(10):1273\u20131299","journal-title":"Future Oncol"},{"issue":"2","key":"6872_CR88","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH (2018) Dendritic Cell-Based cancer vaccines. J Immunol 200(2):443\u2013449","journal-title":"J Immunol"},{"issue":"11","key":"6872_CR89","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.4161\/21645515.2014.982993","volume":"10","author":"AR Pyzer","year":"2014","unstructured":"Pyzer AR, Avigan DE, Rosenblatt J (2014) Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother 10(11):3125\u20133131","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"6872_CR90","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1471-4914(01)01948-7","volume":"7","author":"D Rea","year":"2001","unstructured":"Rea D, Johnson ME, Havenga MJ, Melief CJ, Offringa R (2001) Strategies for improved antigen delivery into dendritic cells. Trends Mol Med 7(3):91\u201394","journal-title":"Trends Mol Med"},{"key":"6872_CR91","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.addr.2020.06.019","volume":"158","author":"DJ Irvine","year":"2020","unstructured":"Irvine DJ, Aung A, Silva M (2020) Controlling timing and location in vaccines. Adv Drug Deliv Rev 158:91\u2013115","journal-title":"Adv Drug Deliv Rev"},{"issue":"17","key":"6872_CR92","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/cells12172147","volume":"12","author":"KW Lee","year":"2023","unstructured":"Lee KW, Yam JWP, Mao X (2023) Dendritic cell vaccines: A shift from conventional approach to new generations. Cells 12(17):2147","journal-title":"Cells"},{"issue":"19","key":"6872_CR93","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/0008-5472.CAN-17-1340","volume":"77","author":"KD Moynihan","year":"2017","unstructured":"Moynihan KD, Irvine DJ (2017) Roles for innate immunity in combination immunotherapies. Cancer Res 77(19):5215\u20135221","journal-title":"Cancer Res"},{"issue":"9","key":"6872_CR94","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.3390\/biomedicines10092292","volume":"10","author":"M Ghosh","year":"2022","unstructured":"Ghosh M, Lenkiewicz AM, Kaminska B (2022) The interplay of tumor vessels and immune cells affects immunotherapy of glioblastoma. Biomed 10(9):2292","journal-title":"Biomedicines"},{"key":"6872_CR95","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3389\/fimmu.2019.02393","volume":"10","author":"J Fucikova","year":"2019","unstructured":"Fucikova J, Palova-Jelinkova L, Bartunkova J, Spisek R (2019) Induction of tolerance and immunity by dendritic cells: mechanisms and clinical applications. Front Immunol 10:2393","journal-title":"Front Immunol"},{"issue":"99","key":"6872_CR96","doi-asserted-by":"crossref","first-page":"eadi3487","DOI":"10.1126\/sciimmunol.adi3487","volume":"9","author":"DM Morgan","year":"2024","unstructured":"Morgan DM, Horton BL, Bhandarkar V, Van R, Dinter T, Zagorulya M et al (2024) Expansion of tumor-reactive CD8(+) T cell clonotypes occurs in the spleen in response to immune checkpoint Blockade. Sci Immunol 9(99):eadi3487","journal-title":"Sci Immunol"},{"key":"6872_CR97","doi-asserted-by":"crossref","first-page":"1039260","DOI":"10.3389\/fimmu.2022.1039260","volume":"13","author":"C Lu","year":"2022","unstructured":"Lu C, Liu Y, Ali NM, Zhang B, Cui X (2022) The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front Immunol 13:1039260","journal-title":"Front Immunol"},{"issue":"1","key":"6872_CR98","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG et al (2023) Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther 8(1):207","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"6872_CR99","doi-asserted-by":"crossref","first-page":"110750","DOI":"10.1016\/j.isci.2024.110750","volume":"27","author":"C Li","year":"2024","unstructured":"Li C, Yu X, Han X, Lian C, Wang Z, Shao S et al (2024) Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy. iScience 27(9):110750","journal-title":"iScience"},{"key":"6872_CR100","first-page":"19","volume":"13","author":"R Kim","year":"2021","unstructured":"Kim R, Kin T (2021) Current and future therapies for Immunogenic cell death and related molecules to potentially cure primary breast cancer. Cancers (Basel) 13:19","journal-title":"Cancers (Basel)"},{"issue":"10","key":"6872_CR101","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3390\/cells14100741","volume":"14","author":"AF Saeed","year":"2025","unstructured":"Saeed AF (2025) Tumor-Associated macrophages: polarization, immunoregulation, and immunotherapy. Cells 14(10):741","journal-title":"Cells"},{"key":"6872_CR102","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semcancer.2019.08.019","volume":"60","author":"C D\u2019Alterio","year":"2020","unstructured":"D\u2019Alterio C, Scala S, Sozzi G, Roz L, Bertolini G (2020) Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin Cancer Biol 60:351\u2013361","journal-title":"Semin Cancer Biol"},{"issue":"3","key":"6872_CR103","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/med.21765","volume":"41","author":"H Sadeghi Rad","year":"2021","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O\u2019Byrne K, Rezaei N et al (2021) Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev 41(3):1474\u20131498","journal-title":"Med Res Rev"},{"issue":"6","key":"6872_CR104","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3892\/ijo.2024.5648","volume":"64","author":"P Su","year":"2024","unstructured":"Su P, Li O, Ke K, Jiang Z, Wu J, Wang Y et al (2024) Targeting tumor\u2013associated macrophages: critical players in tumor progression and therapeutic strategies (Review). Int J Oncol 64(6):60","journal-title":"Int J Oncol"},{"issue":"1","key":"6872_CR105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","volume":"44","author":"S Imani","year":"2025","unstructured":"Imani S, Farghadani R, Roozitalab G, Maghsoudloo M, Emadi M, Moradi A et al (2025) Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy. J Exp Clin Cancer Res 44(1):131","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06872-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06872-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06872-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:39Z","timestamp":1776405579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06872-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":105,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6872"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06872-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"1 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}